Frederick, Maryland (PRWEB) October 20, 2016
BioFactura, Inc. was granted patent rights by China’s State Intellectual Property Office (SIPO) protecting the core technologies of its proprietary StableFastTM Biomanufacturing Platform. SIPO allowed 17 claims broadly covering composition of matter and methods. StableFastTM is BioFactura’s proprietary NS0-based system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible. The Company is developing high-value biosimilars both internally and collaboratively.
“This new allowance continues BioFactura’s 100% success record with multiple patent grants in the US and internationally for StableFast and significantly expands our market exclusivity for NS0-produced biosimilars in China,” said Darryl Sampey, BioFactura’s President and CEO.
Dr. Jeffrey Hausfeld, Chairman and Chief Medical Officer, stated, “The granting of the Chinese patent for BioFactura's StableFast Biomanufacturing Platform further enhances our ability to bring our products to a global market. We are excited about the possibility of providing high-quality, cost-effective biosimilar drugs to patients in China and throughout the Asia.”
BioFactura (Frederick MD) develops and commercializes high-value, highly similar biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.